The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia
Open accessAbstract
BACKGROUND: Accurately monitoring and collecting drug adherence data can allow for better understanding and interpretation of the outcomes of clinical trials. Most clinical trials use a combination of pill counts and self-reported data to measure drug adherence, despite the drawbacks of relying on these types of indirect measures. It is assumed that doses are taken, but the exact timing of these events is often incomplete and imprecise. OBJECTIVE: The objective of this pilot study was to evaluate the use of a novel artificial intelligence (AI) platform (AiCure) on mobile devices for measuring medication adherence, compared with modified directly observed therapy (mDOT) in a substudy of a Phase 2 trial of the α7 nicotinic receptor agonist (ABT-126) in subjects with schizophrenia. METHODS: AI platform generated adherence measures were compared with adherence inferred from drug concentration measurements. RESULTS: The mean cumulative pharmacokinetic adherence over 24 weeks was 89.7% (standard deviation [SD] 24.92) for subjects receiving ABT-126 who were monitored using the AI platform, compared with 71.9% (SD 39.81) for subjects receiving ABT-126 who were monitored by mDOT. The difference was 17.9% (95% CI -2 to 37.7; P=.08). CONCLUSIONS: Using drug levels, this substudy demonstrates the potential of AI platforms to increase adherence, rapidly detect nonadherence, and predict future nonadherence. Subjects monitored using the AI platform demonstrated a percentage change in adherence of 25% over the mDOT group. Subjects were able to use the technology successfully for up to 6 months in an ambulatory setting with early termination rates that are comparable to subjects outside of the substudy. TRIAL REGISTRATION: ClinicalTrials.gov NCT01655680 https://clinicaltrials.gov/ct2/show/NCT01655680?term=NCT01655680.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osterberg, L., & Blaschke, T. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050100 · Cited by 7,974
Tenofovir-based preexposure prophylaxis for HIV infection among African women.
Marrazzo, J. M., Ramjee, G., Richardson, B. A., Gomez, K., Mgodi, N., Nair, G., Palanee, T., Nakabiito, C., van der Straten, A., Noguchi, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1402269 · Cited by 1,296 · cited 1×
“…prevention trial (VOICE) for lack of efficacy, with data suggesting that approximately 70% of the female participants in the study had no measurable tenofovir blood concentrations (the main study drug under investigation) despite approximately 90% of these patients claiming to be adherent [15,16].”
BackgroundFarmer, K. C. (1999) · Clinical Therapeutics · doi:10.1016/s0149-2918(99)80026-5 · Cited by 889
Mobile Interventions for Severe Mental Illness: Design and Preliminary Data From Three Approaches
Depp, C. A., Mausbach, B., Granholm, E., Cardenas, V., Ben-Zeev, D., Patterson, T. L., Lebowitz, B. D., & Jeste, D. V. (2010) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0b013e3181f49ea3 · Cited by 265 · cited 1×
“Acceptance of mobile technology has received little attention in this patient population and has primarily relied on the use of mobile devices for patient self-assessment, and as psychoeducational tools [31,32].”
BackgroundAccurate Assessment of Adherence
Daniels, T., Goodacre, L., Sutton, C., Pollard, K., Conway, S., & Peckham, D. (2011) · Chest · doi:10.1378/chest.09-3074 · Cited by 210
Mitigating the Effects of Nonadherence in Clinical Trials
Shiovitz, T. M., Bain, E. E., McCann, D. J., Skolnick, P., Laughren, T., Hanina, A., & Burch, D. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.689 · Cited by 114
Self-citation
Cited by
Artificial intelligence in drug development: Present status and future prospects
Mak, K.-K., & Pichika, M. R. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.014 · Cited by 1,018
Artificial intelligence for mental health and mental illnesses: an overview
Graham, S., Depp, C., Lee, E. E., Nebeker, C., Tu, X., Kim, H.-C., & Jeste, D. V. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1094-0 · Cited by 970
Fiske, A., Henningsen, P., & Buyx, A. (2019) · Journal of Medical Internet Research · doi:10.2196/13216 · Cited by 857
“Avatars are also being explored in treatment of schizophrenia, for example, to improve medication adherence [23].”
Artificial intelligence powers digital medicine
Fogel, A. L., & Kvedar, J. C. (2018) · npj Digital Medicine · doi:10.1038/s41746-017-0012-2 · Cited by 456
Vatansever, S., Schlessinger, A., Wacker, D., Kaniskan, H. Ü., Jin, J., Zhou, M., & Zhang, B. (2021) · Medicinal Research Reviews · doi:10.1002/med.21764 · Cited by 429
Metadata
- Authors
- Bain, E. E., Shafner, L., Walling, D. P., Othman, A. A., Chuang-Stein, C., Hinkle, J., & Hanina, A.
- Venue
- JMIR mHealth and uHealth
- Publisher
- JMIR Publications Inc.
- Published
- 2017-02-21
- Volume
- 5
- Issue
- 2
- Pages
- e18
- ISSN
- 2291-5222 (ISSN-L)
- OpenAlex
- W2590881186
- Cited by
- 163
- References
- 6
- FWCI
- 9.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia. https://app.cochat.ai/papers/10.2196/mhealth.7030
- The paper
- Bain, E. E., Shafner, L., Walling, D. P., Othman, A. A., Chuang-Stein, C., Hinkle, J., & Hanina, A. (2017). Use of a Novel Artificial Intelligence Platform on Mobile Devices to Assess Dosing Compliance in a Phase 2 Clinical Trial in Subjects With Schizophrenia. JMIR mHealth and uHealth. https://doi.org/10.2196/mhealth.7030
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.